Takeda has announced the appointment of Julie Kim as successor to Christophe Weber, its current president, CEO and representative director, effective from June 2026. The decision was unanimously ...

January 30, 2025--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) announced today that its Board of Directors made the decision unanimously to appoint Julie Kim, currently president of Takeda’s U ...

Takeda has named Julie Kim as its next CEO. She will replace Christophe Weber who plans to step down in June of 2026 after leading Japan’s largest drugmaker for 11 years. The company called the ...

Julie Kim is due to be promoted to chief executive of Takeda Pharmaceutical Co. next year. First, though, the head of the Japanese drugmaker’s US operations had some business advice to share ...

Julie Kim is set to replace Christophe Weber as the new CEO of Takeda Pharmaceutical, becoming the first woman to lead the more than 240-year-old Japanese drugmaker. Kim, 54, has been running ...

Takeda Pharmaceutical 45020.49%increase; green up pointing triangle named Julie Kim, who heads its U.S. business, as its new chief executive starting in 2026, elevating her to the small but ...

He will be replaced by Julie Kim, currently president of Takeda’s U.S. business unit, making her one of the few female chief executives in the pharma industry or of a major Japanese company.

Julie Kim, president of the company's U.S. unit ... opposition from some Takeda shareholders and founding family members. Since Takeda clinched the deal in May 2018, its shares have fallen ...

Takeda CEO Christophe Weber announced he will step down in 2026 and be replaced by Julie Kim, president of Takeda’s U.S. business unit. As part of the executive transition, Weber will retire in June ...

The issuer is solely responsible for the content of this announcement. “The Board of Directors has unanimously chosen Julie Kim to lead Takeda into the next chapter, building on the company’s success ...